SPDR S&P Biotech ETF
651 hedge funds and large institutions have $12.1B invested in SPDR S&P Biotech ETF in 2020 Q4 according to their latest regulatory filings, with 137 funds opening new positions, 232 increasing their positions, 169 reducing their positions, and 33 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding in top 10
Funds holding in top 10: →
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
more capital invested
Capital invested by funds: $ → $
18% more funds holding
Funds holding: 552 → 651 (+99)
5.19% more ownership
Funds ownership: 171.07% → 176.26% (+5.2%)
80% less call options, than puts
Call options by funds: $883M | Put options by funds: $4.34B
Holders
651
Holding in Top 10
16
Calls
$883M
Puts
$4.34B
Top Buyers
| 1 | +$1.69B | |
| 2 | +$566M | |
| 3 | +$555M | |
| 4 |
Wells Fargo
San Francisco,
California
|
+$259M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$258M |
Top Sellers
| 1 | -$1.35B | |
| 2 | -$627M | |
| 3 | -$273M | |
| 4 |
Barclays
London,
United Kingdom
|
-$261M |
| 5 |
Bank of America
Charlotte,
North Carolina
|
-$246M |